Key facts
- This page summarizes Carole Ben-Maimon's Form 4 filing for Larimar Therapeutics, Inc. (LRMR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Jan 2026, 17:04.
Carole Ben-Maimon - 26 Jan 2026 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- LRMR
- Reported as of
- 26 Jan 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Jan 2026, 17:04:08 UTC
- Prior SEC filing
- 24 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Johansson, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Carole Ben-Maimon filed Form 4 for Larimar Therapeutics, Inc. (LRMR) on 27 Jan 2026.
Change
- Previous filing in this sequence was filed on 24 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001529611
Primary reporting owner
BEN-MAIMON CAROLE
- Relationship
- President and CEO, Director
- Address
- C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST, SUITE 506, BALA CYNWYD
- Signature
- /s/ Jennifer Johansson, Attorney-in-fact
- Signature date
- 27 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LRMR
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +100,100
- Change %
- +37%
- Price
- $0.000000
- Shares after
- 368,276
- Date
- 26 Jan 2026
- Ownership
- Direct
- Footnotes
- F1
LRMR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 31,155
- Date
- 26 Jan 2026
- Ownership
- By Trust
- Footnotes
- F2
LRMR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 31,155
- Date
- 26 Jan 2026
- Ownership
- By Trust
- Footnotes
- F3
LRMR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 31,156
- Date
- 26 Jan 2026
- Ownership
- By Trust
- Footnotes
- F4
LRMR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 31,156
- Date
- 26 Jan 2026
- Ownership
- By Trust
- Footnotes
- F5
LRMR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 31,156
- Date
- 26 Jan 2026
- Ownership
- By Trust
- Footnotes
- F6
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LRMR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +600,600
- Change %
- Price
- $0.000000
- Shares after
- 600,600
- Date
- 26 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 600,600
- Exercise price
- $3.60
- Footnotes
- F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
Footnote F2
Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Meadow Lainey Ben-Maimon ("Meadow Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Meadow Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
Footnote F3
Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Olivia Liat Stein ("Olivia Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Olivia Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
Footnote F4
Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Ella Bar Stein ("Ella Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Ella Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
Footnote F5
Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Romi Aleeza Stein ("Romi Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Romi Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
Footnote F6
Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Matzi Mark Ben-Maimon ("Matzi Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Matzi Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
Footnote F7
The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.